11 Celebrities Whose Lives Were Changed by Psychedelics
From Sir Paul McCartney to Joe Rogan, these celebrities all credit psychedelics with changing their lives.
Psychedelic Spotlight News
Interview With Rabbi Zac Kamenetz
Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.
Interview With Douglas K. Gordon
CEO of Silo Wellness, Douglas K. Gordon, speaks about the company’s expansion to the Frankfurt Exchange and the recent collaboration with the Bob Marley Estate.
Psilocybin’s Relationship with Creativity a ‘Complicated’ Affair, Study Finds
New research points to a connection between psilocybin mushrooms and creativity.
Former Texas Gov. Rick Perry Champions Psychedelic Therapy for PTSD
Former Texas Governor, the Republican Rick Perry, is supporting legislation for psychedelic therapy to help veterans with PTSD.
Psilocybin As Effective as Lexapro in Treating Depression: Study
The first study of its kind compares psilocybin and the antidepressant Lexapro in treating depression. The results are promising.
What Is Bicycle Day? Celebrating the First Human LSD Trip
April 19th is Bicycle Day — the first documented case of a human experience on LSD taken by chemist Albert Hoffman.
Digital Therapeutics and Psychedelic Medicines || MindMed ‘s SECRET WEAPON?!?
Digital Therapeutics and Psychedelic Medicines || MindMed’s SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai’s secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.
Instead of doing our usual “This Week In Psychedelic Stocks episode”, I decided to discuss the article entitled “Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP” as it pertains to MindMed and Atai and because there wasn’t a lot of interesting news for our usual Psychedelic segment.
Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there’s two reasons.
1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Time Stamps:
0:00 – Intro
10:08 – Implications for MindMed and Atai
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Interview With Stephen Murphy
Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
Psychedelic Business News Spotlight: April 16, 2021
This week in psychedelic business news:psilocybin’s genome sequencing explored, psychedelics meet artificial intelligence, and more.
End of content
End of content